HROW

Latest SEC Filings & News for HROW

3 most recent filings and news items mentioning HROW. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day
curl "https://api.brieftape.com/v1/tickers/HROW/news?limit=20"

Pull HROW filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day
EarningsAug 10, 2026Positive

Harrow Q2 2026 revenue up 60% sequentially to $70.7M

Harrow reported a 60% sequential revenue increase to $70.7 million for Q2 2026, exceeding revenue guidance and highlighting strong demand across its ophthalmological product portfolio.

View filing at SEC.gov →
M&AAug 6, 2026Positive

Harrow acquires global rights to TYVRAYA dry eye therapy

Harrow will acquire TYVRAYA nasal spray from Viatris for up to $100 million in cash and contingent milestones to expand its ophthalmic portfolio.

View filing at SEC.gov →
OptionsJul 6, 2026Neutral

8 Health Care Stocks With Whale Alerts In Today’s Session

8 Health Care Stocks With Whale Alerts In Today’s Session

View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.